Low molecular weight heparin downregulates tissue factor expression and activity by modulating growth factor receptor-mediated induction of nuclear factor-κB

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 12, 2011, Pages 1591-1600

  Ettelaie, Camille ^a   Fountain, Donna ^a   Collier, Mary Elizabeth W ^a   ElKeeb, Azza M ^a   Xiao, Yu Pei ^b   Maraveyas, Anthony ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Cancer cell lines; Growth factor receptor; Low molecular weight heparin; NF B; Tissue factor

Indexed keywords

BETULIC ACID; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; THROMBOPLASTIN; VASCULOTROPIN;

ARTICLE; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL LINE, TUMOR; DOWN-REGULATION; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION; GENES, REPORTER; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LUCIFERASES; NF-KAPPA B; PROTEIN TRANSPORT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, GROWTH FACTOR; THROMBOPLASTIN; TRANSCRIPTIONAL ACTIVATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80053924442     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.09.007     Document Type: Article

References (50)

1. Tilley R.E., Holscher T., Belani R., Nieva J., Mackman N. Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients. Thromb. Res. 2008, 122:604-609.
2. Khorana A.A., Ahrendt S.A., Ryan C.K., Francis C.W., Hruban R.H., Hu Y.C., Hostetter G., Harvey J., Taubman M.B. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin. Cancer Res. 2007, 13:2870-2875.
3. Haas S.L., Jesnowski R., Steiner M., Hummel F., Ringel J., Burstein C., Nizze H., Liebe S., Löhr J.M. Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation. World J. Gastroenterol. 2006, 12:4843-4849.
4. Khorana A.A., Francis C.W., Menzies K.E., Wang J.G., Hyrien O., Hathcock J., Mackman N., Taubman M.B. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J. Thromb. Haemost. 2008, 6:1983-1985.
5. Hu T., Bach R.R., Horton R., Konigsberg W.H., Todd M.B. Procoagulant activity in cancer cells is dependent on tissue factor expression. Oncol. Res. 1994, 6:321-327.
6. Kasthuri R.S., Taubman M.B., Mackman N. Role of tissue factor in cancer. J. Clin. Oncol. 2009, 27:4834-4838.
7. Khorana A.A. Cancer and thrombosis: implications of published guidelines for clinical practice. Ann. Oncol. 2009, 20:1619-1630.
8. Tesselaar M.E., Romijn F.P.Van, Der Linden I.K., Prins F.A., Bertina R.M., Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J. Thromb. Haemost. 2007, 5:20-27.
9. Zwicker J.I. Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. Thromb. Res. 2010, S2:S89-S91.
10. Zwicker J.I., Liebman H.A., Neuberg D., Lacroix R., Bauer K.A., Furie B.C., Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin. Cancer Res. 2009, 15:6830-6840.
11. Tesselaar M.E., van der Romijn F.P., Linden I.K., Bertina R.M., Osanto S. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J. Thromb. Haemost. 2009, 7:1421-1423.
12. Davila M., Amirkhosravi A., Coll E., Desai H., Robles L., Colon J., Baker C.H., Francis J.L. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J. Thromb. Haemost. 2008, 6:1517-1524.
13. Khorana A.A., Fine R.L. Pancreatic cancer and thromboembolic disease. Lancet Oncol. 2004, 5:655-663.
14. Niers T.M., Brüggemann L.W., Klerk C.P., Muller F.J., Buckle T., Reitsma P.H., Richel D.J., Spek C.A., Van Tellingen O., Van Noorden C.J. Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung. Clin. Ex.p Metastasis 2008, 26:171-178.
15. Nguyên P., Rémy M.G., Potron G. Comparative inhibition of LPS-activated human monocyte-induced thrombin generation by unfractionated heparin and low molecular weight heparins. Haemostasis 1999, 29:301-309.
16. Durand E., Helley D., Al Haj Zen A., Dujols C., Bruneval P., Colliec-Jouault S., Fischer A.M., Lafont A. Effect of low molecular weight fucoidan and low molecular weight heparin in a rabbit model of arterial thrombosis. J. Vasc. Res. 2008, 45:529-537.
17. Kakkar A.K., Williamson R.C. Prevention of venous thromboembolism in cancer using low-molecular-weight heparins. Haemostasis 1997, 27S1:32-37.
18. Maraveyas A., Ettelaie C., Echrish H., Li C., Gardiner E., Greenman J., Madden L.A. Weight-adjusted dalteparin for prevention of vascular thromboembolism in advanced pancreatic cancer patients decreases serum tissue factor and serum-mediated induction of cancer cell invasion. Blood Coagul. Fibrinolysis 2010, 21:452-458.
19. Mackman N. Regulation of the tissue factor gene. Thromb. Haemost. 1997, 78:747-754.
20. Attanasio M., Gori A.M., Giusti B., Pepe G., Comeglio P., Brunelli T., Prisco D., Abbate R., Gensini G.F., Neri Serneri G.G. Cytokine gene expression in human LPS- and IFNγ-stimulated mononuclear cells is inhibited by heparin. Thromb. Haemost. 1998, 79:959-962.
21. Myrvang-Hogasen A.K., Mu J.S., Zhu H.S., Geng J.G. Heparin suppresses lipopolysaccharide-induced monocyte production of several cytokines, but simultaneously stimulates C3 production. Thromb. Res. 1995, 80:179-184.
22. Hochart H., Jenkins P.V., Smith O.P., White B. Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br. J. Haematol. 2006, 133:62-67.
23. Manduteanu I., Voinea M., Antohe F., Dragomir E., Capraru M., Radulescu L., Simionescu M. Effect of enoxaparin on high glucose-induced activation of endothelial cells. Eur. J. Pharmacol. 2003, 477:269-276.
24. Thourani V.H., Brar S.S., Kennedy T.P., Thornton L.R., Watts J.A., Ronson R.S., Zhao Z.Q., Sturrock A.L., Hoidal J.R., Vinten-Johansen J. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 2000, 278:H2084-H2093.
25. Ettelaie C., Collier M.E., James N.J., Li C. Induction of tissue factor expression and release as microparticles in ECV304 cell line by Chlamydia pneumoniae infection. Atherosclerosis 2007, 190:343-351.
26. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 2000, 25:169-193.
27. Li C., Colman L.M., Collier M.E., Dyer C.E., Greenman J., Ettelaie C. Tumour-expressed tissue factor inhibits cellular cytotoxicity. Cancer Immunol. Immunother. 2006, 55:1301-1308.
28. Ettelaie C., Su S., Li C., Collier M.E. Tissue factor-containing microparticles released from mesangial cells in response to high glucose and AGE induce tube formation in microvascular cells. Microvasc. Res. 2008, 76:152-160.
29. Collier M.E., Ettelaie C. Regulation of the incorporation of tissue factor into microparticles by serine phosphorylation of the cytoplasmic domain of tissue factor. J. Biol. Chem. 2011, 286:11977-11984.
30. Collier M.E., Ettelaie C. Induction of endothelial cell proliferation by recombinant and microparticle-tissue factor involves beta1-integrin and extracellular signal regulated kinase activation. Arterioscler. Thromb. Vasc. Biol. 2010, 30:1810-1817.
31. Ettelaie C., Li C., Collier M.E., Pradier A., Frentzou G.A., Wood C.G., Chetter I.C., McCollum P.T., Bruckdorfer K.R., James N.J. Differential functions of tissue factor in the trans-activation of cellular signalling pathways. Atherosclerosis 2007, 194:88-101.
32. Gori A.M., Pepe G., Attanasio M., Falciani M., Abbate R., Prisco D., Fedi S., Giusti B., Brunelli T., Giusti B., Brunelli T., Comeglio P., Gensini G.F., Neri Serneri G.G. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb. Haemost. 1999, 81:589-593.
33. Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., Patel H.K., Rustin G., Thomas M., Quigley M., Williamson R.C. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 2004, 22:1944-1948.
34. Klerk C.P., Smorenburg S.M., Otten H.M., Lensing A.W., Prins M.H., Piovella F., Prandoni P., Bos M.M., van Richel D.J., Tienhoven G., Büller H.R. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 2005, 23:2130-2135.
35. Altinbas M., Coskun H.S., Er O., Ozkan M., Eser B., Unal A., Cetin M., Soyuer S. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J. Thromb. Haemost. 2004, 2:1266-1271.
36. Li Q., Li Y., Wang X., Fang X., He K., Guo X., Zhan Z., Sun C., Jin Y.H. Co-treatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release. Mol Carcinog. 2011, 50:760-769.
37. Jiang M., Zhou Y., Yang M., Zhang R., Zou M., Cai G., Pan D. Influence of betulinic acid on proliferation, migration, cell cycle and apoptosis of pancreatic cancer cells. Zhongguo Zhong Yao Za Zhi 2010, 35:3056-3059.
38. Kommera H., Kaluderović G.N., Kalbitz J., Paschke R. Lupane triterpenoids-betulin and betulinic acid derivatives induce apoptosis in tumor cells. Invest. New Drugs 2011, 29:266-272.
39. Schecter A.D., Giesen P.L., Taby O., Rosenfield C.L., Rossikhina M., Fyfe B.S., Kohtz D.S., Fallon J.T., Nemerson Y., Taubman M.B. Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J. Clin. Invest. 1997, 100:2276-2285.
40. Nemerson Y., Giesen P.L. Some thoughts about localization and expression of tissue factor. Blood Coagul. Fibrinolysis 1998, 9Sl:S45-S47.
41. Lin P., Sinha U., Betz A. Antithrombin binding of low molecular weight heparins and inhibition of factor Xa. Biochim. Biophys. Acta 2001, 1526:105-113.
42. Zanon C., Bortolini M., Chiappino I. Low-molecular-weight heparin and calcium heparin in thrombosis prophylaxis in patients with percutaneous arterial and venous ports for colorectal liver metastases. Tumori 2005, 91:477-480.
43. Gerotziafas G.T., Samama M.M. Prophylaxis of venous thromboembolism in medical patients. Curr. Opin. Pulm. Med. 2004, 10:356-365.
44. Ulbrich C., Westphal K., Baatout S., Wehland M., Bauer J., Flick B., Infanger M., Kreutz R., Vadrucci S., Egli M., Cogoli A., Derradji H., Pietsch J., Paul M., Grimm D. Effects of basic fibroblast growth factor on endothelial cells under conditions of simulated microgravity. J. Cell. Biochem. 2008, 104:1324-1341.
45. Mentlein R., Forstreuter F., Mehdorn H.M., Held-Feindt J. Functional significance of vascular endothelial growth factor receptor expression on human glioma cells. J. Neurooncol. 2004, 67:9-18.
46. Moehler M., Frings C., Mueller A., Gockel I., Schimanski C.C., Biesterfeld S., Galle P.R., Holtmann M.H. VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab. World J. Gastroenterol. 2008, 14:4156-4167.
47. Bucci B., D'Agnano I., Botti C., Mottolese M., Carico E., Zupi G., Vecchione A. EGF-R expression in ductal breast cancer: proliferation and prognostic implications. Anticancer Res. 1997, 17:769-774.
48. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5:341-354.
49. von Delius S., Ayvaz M., Wagenpfeil S., Eckel F., Schmid R.M., Lersch C. Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma. Thromb. Haemost. 2007, 98:434-439.
50. Signaevsky M., Hobbs J., Doll J., Liu N., Soff G.A. Role of alternatively spliced tissue factor in pancreatic cancer growth and angiogenesis. Semin. Thromb. Hemost. 2008, 34:161-169.